Chemical Biology and Drug Design

DECEMBER 15, 2022

The microtubule targeting agents plinabulin, docetaxel, and vinblastine interrupt MT polymerization by altering both MT conformation and binding free energy of the neighboring tubulin subunits. Abstract The natural products plinabulin, docetaxel, and vinblastine are microtubule targeting agents (MTAs). They have been used alone or in combination in cancer treatment.

Production 100

Production Treatment Drugs Research 100

Antidote

DECEMBER 12, 2022

Osteoporosis, a disease that causes the bones to become brittle and porous, can significantly impact a person’s quality of life. It is the most common bone disease in the world, impacting about 54 million people — but many people are not diagnosed with osteoporosis until after a fracture occurs.

Disease 98

Disease 98

Drug Channels

DECEMBER 12, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Click here to see the original post and comments from September 2022. During Friday’s webinar, I’ll be sharing my updated thoughts about the IRA’s impact on manufacturers, Part D plans, and patient behavior. By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. 117-169).

Biosimilars 97

Biosimilars Pharmacy Hospitals Marketing 97

Drug Patent Watch

DECEMBER 15, 2022

This chart shows the pharmaceutical companies with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 90

Pharmaceutical Companies Pharmaceuticals Drugs 90

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Cytel

DECEMBER 16, 2022

Bayesian methods have been playing a key role in transforming clinical research, and Bayesian topics are frequently featured in Cytel’s Perspectives on Enquiry and Evidence. Our new ebook features a set of articles exploring various topics related to Bayesian statistical methods.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Development 52

The ChEMBL-og

DECEMBER 16, 2022

The ChEMBL Team heads off soon on their Christmas holidays! Before we leave, we would like to remember some highlights of 2022 and share some outlook for the next year! 2022 was an extraordinary year for the UK and also for the ChEMBL Team! It was a year of celebrations, farewells, and new beginnings. The ChEMBL team underwent major personnel changes in 2022 , with Anna and Patricia leaving the team, and Barbara, Eloy and Fiona taking on new roles within the ChEMBL leadership team. 2022 was a ye

Science 52

Science Research 52

Drug Patent Watch

DECEMBER 16, 2022

This chart shows the pharmaceutical companies with the most patents in New Zealand. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical companies have the most drug patents in New Zealand? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 65

Pharmaceutical Companies Pharmaceuticals Drugs 65

The Premier Consulting Blog

DECEMBER 14, 2022

Digital health products are widely used for the prevention, diagnosis, treatment, and management of health and disease. The introduction of digital medicines—and, more recently, digital therapeutics (DTx)—has begun to influence the treatment and management of certain diseases, both by consumers and by clinicians. Driven by advances in technology and increased acceptance of telehealth, digital medicines and DTx are poised to become an integral part of the healthcare model.

Production 52

Production Regulations Therapies Disease 52

Crown Bioscience

DECEMBER 15, 2022

3D adult stem cell (ASC)-derived tumor organoids can enhance the translatability of drug discovery data, especially in combination with high content imaging (HCI). In this blog post, we explore how the pairing of these two technologies allows researchers to develop highly comprehensive and predictive data that can enable better decisions earlier in drug discovery, while improving the translatability of the most promising lead compounds.

Drugs 52

Drugs Research 52

Drug Channels

DECEMBER 14, 2022

This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Outlook 2023. In the four months since I published the article below, the issues with alternative funding programs have hit the mainstream press. Check out last week's article from Kaiser Health News: Employers Use Patient Assistance Programs to Offset Their Own Costs.

Pharmacy 82

Pharmacy Compliance Drugs 82

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Patent Watch

DECEMBER 16, 2022

Annual Drug Patent Expirations for VARUBI Varubi is a drug marketed by Tersera and is included in two NDAs. It is available from one supplier. There are nine patents protecting…. The post New patent expiration for Tersera drug VARUBI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

National Institute on Drug Abuse: Nora's Blog

DECEMBER 14, 2022

NIH Invests in a New Harm Reduction Research Network mfleming Wed, 12/14/2022 - 19:34 Nora's Blog December 16, 2022 Image ©Getty Images/ Maskot The need to save lives and reduce negative health outcomes from drug use is unprecedented. In 2021 alone, the overdose epidemic took the lives of more than 107,000 people in the U.S., according to provisional data from the Centers for Disease Control and Prevention.

Research 52

Research Treatment Disease Drugs 52

Antidote

DECEMBER 15, 2022

At Antidote, we believe that all members of society should be equally represented — especially when it comes to medical research. Historically, racial and ethnic minorities have been under-represented in the clinical trial space , and continue to face challenges when trying to access healthcare today.

Clinical Trials 52

Clinical Trials Trials Research 52

Drug Channels

DECEMBER 16, 2022

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels Outlook 2023. ICYMI, the Health Resources and Services Administration (HRSA) finally got tired of my Freedom of Information Act (FOIA) requests. Shortly after I published the article below, HRSA posted public data about 340B covered entity purchases on its website.

Hospitals 74

Hospitals Drugs Pharmacy 74

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Patent Watch

DECEMBER 15, 2022

Annual Drug Patent Expirations for XYOSTED+%28AUTOINJECTOR%29 Xyosted (autoinjector) is a drug marketed by Antares Pharma Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Antares Pharma drug XYOSTED (AUTOINJECTOR) appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advarra

DECEMBER 15, 2022

As the research community continues to seek clinical trial efficiencies designed to bring therapies to patients faster, more governing bodies are pushing for single institutional review board (single IRB) review as one way to streamline efforts. To better understand what sIRB review requirements mean for sites and sponsors, it’s important to first understand what an single IRB is and how it works.

Clinical Trials 52

Clinical Trials Regulations FDA Trials 52

Cytel

DECEMBER 14, 2022

When evaluating the efficacy of a candidate investigational therapy, a standard clinical trial paradigm is to conduct a two-arm randomized trial, typically evaluating that therapy against a control arm. And if multiple therapies are being evaluated against the same disease, there may be multiple parallel two-arm trials. However, this creates redundancies, wasting time and resources.

Trials 52

Trials Clinical Trials Therapies Disease 52

Drug Channels

DECEMBER 13, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Click here to see the original post and comments from August 2022. Over the weekend, the U.S. Senate passed a massive overhaul of the Medicare Part D program. If passed into law, these changes will have many unintended consequences , but will not address the warped incentives baked into our current rebate system.

Pharmacy 67

Pharmacy Drugs 67

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

DECEMBER 15, 2022

Annual Drug Patent Expirations for FINTEPLA Fintepla is a drug marketed by Zogenix Inc and is included in one NDA. It is available from one supplier. There are twelve patents…. The post New patent for Zogenix Inc drug FINTEPLA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

EG Life Sciences

DECEMBER 14, 2022

As we approach the end of 2022, it could not be a better time to go through some important and fascinating breakthroughs from the year that propelled us toward significant advancements within the life sciences space. The future is now, and innovative technology has changed the world, forcing the Biotech/Pharma and Med-Device sectors to transform their process.

Science 52

Science 52

keypoint

DECEMBER 14, 2022

Announcing Keystone Symposia's new Chief Scientific Officer, Dr. Terry Sheppard, formerly founding Chief Editors at Nature Chemical Biology, and the retirement of current CSO Dr. Thale Jarvis.

52

52

Conversations in Drug Development Trends

DECEMBER 12, 2022

Genetic testing provides patients with a diagnosis for their illness, helps patients and family members to understand risks of developing new diseases, and can be used to support clinical trial advancement. Worldwide Clinical Trials ​​has partnered with the leading medical genetics company, Invitae , making Worldwide ​​the first CRO to use Invitae’s Explorer tool.

Clinical Trials 52

Clinical Trials Trials Laboratories Research Laboratories 52

Drug Patent Watch

DECEMBER 15, 2022

Annual Drug Patent Expirations for VANCOMYCIN+HYDROCHLORIDE Vancomycin Hydrochloride is a drug marketed by Akorn, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Strides Pharma, Watson Labs, Aspiro, Emcure Pharms…. The post New patent for Xellia Pharms drug VANCOMYCIN HYDROCHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

ProRelix Research

DECEMBER 12, 2022

The post-pandemic clinical trial landscape has paved way for the integration of technology, data analytics, and digitization to facilitate all aspects of trial management from patient identification and recruitment to […]. The post What is eCOA and ePRO? appeared first on ProRelix Research.

Clinical Trials 52

Clinical Trials Trials Research 52

Predictive Oncology

DECEMBER 16, 2022

We sat down for a Q&A with investors in a conversation moderated by Shareholder Nathan Reese. Watch our recording of the webcast here. The post Shareholder Q&A appeared first on Predictive Oncology.

40

40

Translation

DECEMBER 13, 2022

The J.P. Morgan 41st Annual Healthcare Conference , otherwise known as JPM 2023, is returning in-person to San Francisco for the first time in two years. The event is set to take place from January 9 – 12, 2023 , and, with it, comes a host of networking events and afterparties. Craft cocktail classes on Zoom won’t cut it this year. Why attend networking events at JPM 2023?

Science 40

Science Research 40

Drug Patent Watch

DECEMBER 15, 2022

Annual Drug Patent Expirations for KLISYRI Klisyri is a drug marketed by Almirall and is included in one NDA. It is available from one supplier. There are seven patents protecting…. The post New patent for Almirall drug KLISYRI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

LifeSciVC

DECEMBER 13, 2022

Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones. As a potential best-in-class asset in the significant new therapeutic category of selective Tyk2 inhibition, our recent Phase 2b data set the stage for a broad Phase 3 campaign. Partnering with Takeda will accelerate this potential therapeutic reaching its full potential.

Clinical Trials 40

Clinical Trials Trials Engineering Disease 40

Zobio

DECEMBER 12, 2022

The availability of 3D structural information plays a vital role in modern drug discovery programs. At ZoBio we deeply understand this and have invested heavily in building a team and a lab to create a powerful X-ray crystallography workflow specifically. Het bericht The Upgrade of X-Ray Crystallography Infrastructure Completed verscheen eerst op ZoBio - Drug Discovery Technology.

Drugs 40

Drugs 40

Advarra

DECEMBER 14, 2022

Effective as of 2007, Medicare has offered coverage for routine costs in clinical trials. However, in order to be eligible for extended coverage under a clinical trial, several requirements must be met. The checklist below offers a step-by-step process to determine whether your clinical trial meets the requirements of the National Coverage Determination (NCD) for Routine Costs in Clinical Trials.

Clinical Trials 52

Clinical Trials Trials Compliance Pharmacokinetics 52

Drug Patent Watch

DECEMBER 15, 2022

Annual Drug Patent Expirations for PEDMARK Pedmark is a drug marketed by Fennec Pharms Inc and is included in one NDA. There are two patents protecting this drug. This drug…. The post New patent for Fennec Pharms drug PEDMARK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug & Device Law

DECEMBER 15, 2022

Twice this year we have reported on trial-court decisions addressing application of offensive non-mutual collateral estoppel—an offensive doctrine that precludes a defendant from relitigating an issue that it lost in earlier litigation against a different plaintiff. One court applied it; the other refused to. Today we report on a Sixth Circuit decision that affirmed, over a spirited dissent, application of the doctrine in a follow-on MDL case.

Trials 64

Trials Government International Disease 64

Drug Patent Watch

DECEMBER 14, 2022

Annual Drug Patent Expirations for DORYX Doryx is a drug marketed by Mayne Pharma Intl, Warner Chilcott, and Mayne Pharma and, and is included in three NDAs. It is available…. The post New patent expiration for Mayne Pharma drug DORYX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52